- Home
- / Innate Pharma
Innate Pharma
Stock Price
€2.7
2023-08-28
Market Capitalization
€248.6 M
2023-08-28
Revenue
€49.8 M
FY, 2022
Innate Pharma Summary
Company Summary
- Overview
- Innate Pharma is a clinical-stage biotechnology company with a focus on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. The company’s aim is a commercial-stage biopharmaceutical company in the area of immunotherapy and focuses on the research in medical needs in cancer.
- Type
- Public
- Status
- Active
- Founded
- 1999
- HQ
- Marseille, FR | view all locations
- Cybersecurity rating
- ESG rating
- Sectors
Table of Contents
Key People
Odile Laurent, Vice President, Human Resources Director
Irina Staatz-Granzer, Vice-Chairman
Mondher Mahjoubi, Chairman of the Executive Board and Chief Executive Officer
Operating MetricsView all
Phase I Trials Products
3
Q2, 2019
Pre-Clinical Phase Products
7
Q2, 2019
Phase II Trials Products
5
Q2, 2019
LocationsView all
2 locations detected
Marseille, Provence-Alpes-Côte d'Azur HQ
France
117 Avenue de Luminy
Rockville, MD
United States
2273 Research Blvd #350
Innate Pharma Financials
Summary Financials
- Revenue (FY, 2022)
- €49.8M
- Gross profit (FY, 2022)
- €57.4M
- Net income (FY, 2022)
- (€58.1M)
- Cash (FY, 2022)
- €84.2M
- EBIT (FY, 2022)
- (€57.5M)
- Enterprise value
- $206.6M